BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 15847006)

  • 1. Tissue-specific Cushing's syndrome uncovers a new target in treating the metabolic syndrome--11beta-hydroxysteroid dehydrogenase type 1.
    Stewart PM
    Clin Med (Lond); 2005; 5(2):142-6. PubMed ID: 15847006
    [No Abstract]   [Full Text] [Related]  

  • 2. Adipose tissue expression of 11beta-hydroxysteroid dehydrogenase type 1 in Cushing's syndrome and in obesity.
    Espíndola-Antunes D; Kater CE
    Arq Bras Endocrinol Metabol; 2007 Nov; 51(8):1397-403. PubMed ID: 18209879
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 11β-Hydroxysteroid dehydrogenase type 1: relevance of its modulation in the pathophysiology of obesity, the metabolic syndrome and type 2 diabetes mellitus.
    Pereira CD; Azevedo I; Monteiro R; Martins MJ
    Diabetes Obes Metab; 2012 Oct; 14(10):869-81. PubMed ID: 22321826
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tissue-specific glucocorticoid reactivating enzyme, 11 beta-hydroxysteroid dehydrogenase type 1 (11 beta-HSD1)--a promising drug target for the treatment of metabolic syndrome.
    Masuzaki H; Flier JS
    Curr Drug Targets Immune Endocr Metabol Disord; 2003 Dec; 3(4):255-62. PubMed ID: 14683456
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selective inhibitors of 11beta-hydroxysteroid dehydrogenase type 1 for patients with metabolic syndrome: is the target liver, fat, or both?
    Stewart PM; Tomlinson JW
    Diabetes; 2009 Jan; 58(1):14-5. PubMed ID: 19114723
    [No Abstract]   [Full Text] [Related]  

  • 6. 11beta-hydroxysteroid dehydrogenase type 1 and obesity.
    Morton NM; Seckl JR
    Front Horm Res; 2008; 36():146-164. PubMed ID: 18230901
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glucocorticoids and 11beta-hydroxysteroid dehydrogenase type 1 in obesity and the metabolic syndrome.
    Stimson RH; Walker BR
    Minerva Endocrinol; 2007 Sep; 32(3):141-59. PubMed ID: 17912154
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 11beta-hydroxysteroid dehydrogenase type 1 inhibitors for the treatment of type 2 diabetes.
    Morgan SA; Tomlinson JW
    Expert Opin Investig Drugs; 2010 Sep; 19(9):1067-76. PubMed ID: 20707593
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glucocorticoids and 11beta-hydroxysteroid dehydrogenase in adipose tissue.
    Seckl JR; Morton NM; Chapman KE; Walker BR
    Recent Prog Horm Res; 2004; 59():359-93. PubMed ID: 14749510
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prenatal programming of metabolic syndrome in the common marmoset is associated with increased expression of 11beta-hydroxysteroid dehydrogenase type 1.
    Nyirenda MJ; Carter R; Tang JI; de Vries A; Schlumbohm C; Hillier SG; Streit F; Oellerich M; Armstrong VW; Fuchs E; Seckl JR
    Diabetes; 2009 Dec; 58(12):2873-9. PubMed ID: 19720800
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of 11beta-hydroxysteroid dehydrogenase type 1 in obesity.
    Wake DJ; Walker BR
    Endocrine; 2006 Feb; 29(1):101-8. PubMed ID: 16622297
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 11-Beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD1) inhibitors in type 2 diabetes mellitus and obesity.
    Hughes KA; Webster SP; Walker BR
    Expert Opin Investig Drugs; 2008 Apr; 17(4):481-96. PubMed ID: 18363514
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of 11beta-hydroxysteroid dehydrogenase type 1 as a promising therapeutic target.
    Wamil M; Seckl JR
    Drug Discov Today; 2007 Jul; 12(13-14):504-20. PubMed ID: 17631244
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adipose tissue 11beta-hydroxysteroid dehydrogenase type 1 expression in obesity and Cushing's syndrome.
    Mariniello B; Ronconi V; Rilli S; Bernante P; Boscaro M; Mantero F; Giacchetti G
    Eur J Endocrinol; 2006 Sep; 155(3):435-41. PubMed ID: 16914598
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In the lipodystrophy associated with highly active antiretroviral therapy, pseudo-Cushing's syndrome is associated with increased regeneration of cortisol by 11beta-hydroxysteroid dehydrogenase type 1 in adipose tissue.
    Sutinen J; Kannisto K; Korsheninnikova E; Nyman T; Ehrenborg E; Andrew R; Wake DJ; Hamsten A; Walker BR; Yki-Järvinen H
    Diabetologia; 2004 Oct; 47(10):1668-71. PubMed ID: 15455200
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Extra-adrenal regeneration of glucocorticoids by 11beta-hydroxysteroid dehydrogenase type 1: physiological regulator and pharmacological target for energy partitioning.
    Walker BR
    Proc Nutr Soc; 2007 Feb; 66(1):1-8. PubMed ID: 17343766
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MECHANISMS IN ENDOCRINOLOGY: Tissue-specific activation of cortisol in Cushing's syndrome.
    Morgan SA; Hassan-Smith ZK; Lavery GG
    Eur J Endocrinol; 2016 Aug; 175(2):R83-9. PubMed ID: 26957494
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Down-regulation of adipose 11beta-hydroxysteroid dehydrogenase type 1 by high-fat feeding in mice: a potential adaptive mechanism counteracting metabolic disease.
    Morton NM; Ramage L; Seckl JR
    Endocrinology; 2004 Jun; 145(6):2707-12. PubMed ID: 15044372
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 11beta-hydroxysteroid dehydrogenase type 1 as a novel therapeutic target in metabolic and neurodegenerative disease.
    Walker BR; Seckl JR
    Expert Opin Ther Targets; 2003 Dec; 7(6):771-83. PubMed ID: 14640912
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is there visceral adipose tissue (VAT) intracellular hypercortisolism in human obesity?
    Alfonso B; Araki T; Zumoff B
    Horm Metab Res; 2013 May; 45(5):329-31. PubMed ID: 23549672
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.